Skip to main content

Market Overview

UPDATE: Canaccord Genuity Lowers PT on Allergan on Disappointments Hitting Sentiment


In a report published Tuesday, Canaccord Genuity analyst Randall Stanicky lowered the price target on Allergan (NYSE: AGN) from $111 to $98 and reiterated a Hold rating on the company.

In the report, Canaccord Genuity commented, "With yesterday’s 12% RESTASIS driven sell-off, AGN shares are down 29% from mid-April year highs on the back of three disappointments that have also hit sentiment including (1) the LEVADEX complete response letter; (2) the DARPin set-back; and now (3) the RESTASIS draft FDA guidance that drove several recent downgrades. While our initial reaction is to go the other way and upgrade AGN as a RESTASIS generic now feels fully priced in and the stock is at trough valuation levels, we still lack catalysts needed for a sustained reversal."

Allergan closed Monday at $81.99.

Latest Ratings for AGN

Apr 2020SunTrust Robinson HumphreyDowngradesBuyHold
Mar 2020CFRADowngradesBuyHold
Feb 2020SunTrust Robinson HumphreyMaintainsBuy

View More Analyst Ratings for AGN
View the Latest Analyst Ratings


Related Articles (AGN)

View Comments and Join the Discussion!

Posted-In: Canaccord Genuity Randall StanickyAnalyst Color Price Target Analyst Ratings

Latest Ratings

COFPiper SandlerMaintains164.0
DFSPiper SandlerMaintains103.0
THGJMP SecuritiesMaintains145.0
TTEKMaxim GroupMaintains160.0
SIGIJMP SecuritiesMaintains80.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at